CLOUDR GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.84 HKD | +7.98% |
|
+19.83% | -58.54% |
| Apr. 15 | ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services | MT |
| Mar. 22 | ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5% | MT |
| Sales 2023 | 3.69B 509M 3.99B | Sales 2024 * | 4.81B 664M 5.2B | Capitalization | 1.43B 197M 1.54B |
|---|---|---|---|---|---|
| Net income 2023 | -323M -44.58M -349M | Net income 2024 * | -77M -10.63M -83.2M | EV / Sales 2023 | 0.99 x |
| Net cash position 2023 * | 914M 126M 987M | Net cash position 2024 * | 470M 64.87M 508M | EV / Sales 2024 * | 0.2 x |
| P/E ratio 2023 |
-10.4
x | P/E ratio 2024 * |
-12.5
x | Employees | 1,522 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 75.24% |
More Fundamentals
* Assessed data
More news
| 1 day | +7.60% | ||
| 1 week | +17.92% | ||
| Current month | +8.85% | ||
| 1 month | +2.54% | ||
| 3 months | -50.09% | ||
| 6 months | -56.33% | ||
| Current year | -58.69% |
1 week
2.35
2.85
1 month
2.113.09
Current year
2.116.85
1 year
2.1110.18
3 years
2.1130.70
5 years
2.1130.70
10 years
2.1130.70
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Kuang
CEO | Chief Executive Officer | 43 | 14-12-08 |
Li Li Xu
DFI | Director of Finance/CFO | 43 | 20-09-30 |
Jing Xu Wang
PRN | Corporate Officer/Principal | 55 | 18-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Li Hong
BRD | Director/Board Member | 61 | 22-06-30 |
Kar Chung Lee
BRD | Director/Board Member | 43 | 21-05-20 |
Sai Yin Zhang
BRD | Director/Board Member | 44 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.84 | +7.98% | 19 907 800 |
| 24-04-25 | 2.63 | -0.38% | 14,188,500 |
| 24-04-24 | 2.64 | +8.64% | 20,518,900 |
| 24-04-23 | 2.43 | +0.41% | 7,393,653 |
| 24-04-22 | 2.42 | +0.83% | 5,049,900 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
ClouDr Group Ltd is a China-based holding company principally engaged in the provision of medical services and products. The Company provides medical supplies and software-as-a-service (SaaS) products to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultations and prescriptions to patients. The Company's product portfolio consists of three major product or service categories. The in-hospital solution mainly includes hospital supplies sales, hospital SaaS and digital marketing services. The pharmacy solution mainly includes pharmacy supplies sales and pharmacy SaaS. The individual chronic condition management solution and others mainly include chronic condition products, premium membership services, as well as insurance brokerage services, advertisement agent services and others.
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.434
CNY
Average target price
7.134
CNY
Spread / Average Target
+193.11%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -58.69% | 197M | |
| -2.92% | 185B | |
| -3.80% | 105B | |
| -5.48% | 66.59B | |
| +11.22% | 54.66B | |
| +16.74% | 47.78B | |
| +4.06% | 41.26B | |
| +4.56% | 26.95B | |
| +1.64% | 26.37B | |
| +12.96% | 24.8B |
- Stock Market
- Equities
- 9955 Stock
